TABLE 5.
Previous reports of preoperative DCF with prophylactic use of pegfilgrastim.
| Author | Ref | Year | Type of study | Docetaxel | Cisplatin | Fluorouracil | |
|---|---|---|---|---|---|---|---|
| (mg/m2) | (mg/m2) | (mg/m2) | |||||
| 1 | Yoshida | 17 | 2018 | Retrospective | 70 | 70 | 700 × 5 |
| 2 | Kawahira | 18 | 2018 | Retrospective | 70 | 70 | 750 × 5 |
| 3 | Ohkura | 19 | 2019 | Retrospective | 75 | 75 | 750 × 5 |
| 4 | Okamoto | 20 | 2022 | Retrospective | 60–70 | 60–70 | 750 − 800 × 5 |
| 5 | Ishikawa | 11 | 2019 | Prospective | 70 | 70 | 750 × 5 |
| 6 | Maeda | 10 | 2022 | Prospective | 70 | 70 | 750 × 5 |
| 7 | Present study | Prospective | 70 | 70 | 750 × 5 |
| Administration of G‐CSF | Antibiotics | Number of | G4 neutropenia | Febrile neutropenia | |||
|---|---|---|---|---|---|---|---|
| patients | n | (%) | n | (%) | |||
| 1 | Pegfilgrastim on day 7 or later | (not described) | 35 a | 4 | 11.4 | 4 | 11.4 |
| 2 | Filgrastim or pegfilgrastim on day 7 | CPFX or LVFX days 5–15 | 26 | 11 | 42.3 | 8 | 30.8 |
| 3 | Pegfilgrastim on day 7 | None | 33 | – | – | 1 | 3.0 |
| 4 | Pegfilgrastim on day 7 | (not described) | 65 | 10 | 15.4 | 8 | 12.3 |
| 5 | Pegfilgrastim on day 3 | LVFX on days 5–9 | 23 | 2 | 8.7 | 0 | 0 |
| 6 | Pegfilgrastim on day 7 | None | 37 | 11 | 29.7 | 11 | 29.7 |
| 7 | Pegfilgrastim on day 3 | 26 | 10 | 38.5 | 2 | 7.7 | |
| None | 14 | 4 | 28.6 | 2 | 14.3 | ||
| LVFX on days 5–9 | 12 | 6 | 50 | 0 | 0 | ||
a
Number of administrations.
Abbreviations: CPFX, ciprofloxacin; LVFX, levofloxacin.